Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE sleep apnea randomized clinical trial
In North America, 3040% of patients with mCRPC do not respond to initial docetaxel treatment, and in Asia, up to 45% of patients may not benefit from docetaxel-based therapy (27)
Acknowledgements The authors acknowledge the support of grants from Inserm, CNRS, Universit Paris Cit, Agence Nationale de la Recherche (ANR), Socit Francophone du Diabte (SFD), Fondation pour la Recherche Mdicale (FRM), the Dutch Organization for Scientific Research (ZonMW) and DiabetesFonds
Beyond their established role in the treatment of T2DM and obesity, GLP-1 RAs are increasingly being investigated for their therapeutic potential in a broad spectrum of metabolic diseases due to their pleiotropic actions, which affect glucose and lipid regulation, inflammation, and organ function
For many people, silenced food noise is the single biggest change a GLP-1 brings - and the one hardest to prove to anyone, including yourself, without a log
Dosing and Administration# GHRP-6 Dosing# Typical research dose : 100-300 mcg per administration, subcutaneous Frequency : 2-3 times daily Timing : Best administered on an empty stomach
